ArticlePsychopharmacology2009
Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.
Article in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- The genetics of drug-related movement disorders, an umbrella review of meta-analyses.Molecular psychiatry · 2020Pooled it
- Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009Pooled it
- Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.Psychopharmacology · 2020Trial
- Description of schizophrenia treatment outcomes in Saudi Arabia: A preliminary pilot investigation.The Journal of international medical research · 2025Article
- Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients.Biomedicines · 2021Review
- Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.Behavioral sciences (Basel, Switzerland) · 2021Review
- Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.Frontiers in psychiatry · 2018Article
- NOVA1 acts as an oncogene in osteosarcoma.American journal of translational research · 2017Article
- Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.The pharmacogenomics journal · 2016Article
- Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.Frontiers in neurology · 2015Review
- Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).Omics : a journal of integrative biology · 2014Article
- Pharmacogenetics of antipsychotics.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2014Review
- Genome-wide association studies in pharmacogenomics: successes and lessons.Pharmacogenetics and genomics · 2013Review
- Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.ISRN pharmacology · 2013Article
- Pharmacogenetics in psychiatry: translating research into clinical practice.Molecular psychiatry · 2012Review
- Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.Psychopharmacology · 2012Article
- Drug-induced parkinsonism in the elderly: incidence, management and prevention.Drugs & aging · 2012Review
- Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.Psychopharmacology · 2012Article
- Article
- Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
rationaleAntipsychotic-induced parkinsonism (AIP) is a severe adverse affect of neuroleptic treatment. Interindividual heterogeneity in AIP development and severity is associated with risk factors such as antipsychotic drug type, old age, and female gender. There is evidence for genetic predisposition to develop AIP but the variants that confer susceptibility or protection are mostly unknown.
objectiveTo identify genes related to AIP susceptibility, we performed a pharmacogenomic genome-wide association study (GWAS) for AIP severity.
methodsThree hundred ninety-seven American schizophrenia patients who participated in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-GWAS project were included in our analysis. Patients had been randomized to treatment with antipsychotic monotherapy for periods ranging from 2 weeks to 18 months during phase 1 of the CATIE trial. They were regularly assessed for AIP severity using the modified Simpson-Angus Scale (SAS). For statistical analysis, patients were dichotomized as cases (average SAS mean global score > 0.3 during CATIE phase 1, N = 199) or controls (average SAS mean global score 0, N = 198).
resultsUsing logistic regression and controlling for population stratification, age, gender, SAS score at baseline, and concomitant use of anticholinergic drugs, we identified several single-nucleotide polymorphisms associated with AIP severity. Although none reached the GWAS significance level of P < 4.2 x 10(-7), some promising candidate genes for further research on genetic predisposition to AIP were identified including EPF1, NOVA1, and FIGN.
conclusionsOur finding may contribute to understanding of the pathophysiology of AIP as well as to a priori identification of patients vulnerable for development of AIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.